SUPERMX: Despite Recent Setbacks, Analyst Sees Significant Upside Potential
| Investment Bank | TA SECURITIES |
|---|---|
| TP (Target Price) | RM0.25 |
| Last Traded | RM0.20 |
| Recommendation |
An investment bank has reiterated its “BUY” recommendation for a prominent glove manufacturer, citing a favorable risk-reward balance and potential policy catalysts, despite the company’s recent financial performance falling below expectations. The target price has been set at RM0.25, suggesting a significant upside from its last traded price of RM0.20.
Financial Performance Review
The company reported a widened core loss of RM49.3 million for the second quarter of financial year 2026 (2QFY26), contributing to a half-year core loss of RM64 million. Quarterly revenue also saw a decline of 9% quarter-on-quarter and 6% year-on-year, settling at RM187 million. These results missed both the investment bank’s and consensus forecasts.
Operational Challenges and Headwinds
Operational setbacks were primarily attributed to initial start-up costs at its US plant. Further headwinds included an estimated 9% quarter-on-quarter decline in sales volumes and the strengthening of the Malaysian Ringgit, which together offset any gains from higher average selling prices. A notable 9% surge in core operating expenses, largely driven by pre-operating costs in the US, overshadowed ongoing efficiency improvements and led to a negative EBITDA of RM37 million. The report also highlighted a resumption of cash burn, with net cash narrowing to RM596 million.
Strategic Outlook and Catalysts for Growth
Despite these challenges, the investment bank views the current situation as a tactical positioning opportunity. The company is navigating a “perfect storm,” facing high US operational expenses concurrently with the weakening of federal protection from 19-20% International Emergency Economic Powers Act (IEEPA) tariffs on ASEAN imports, following a recent legal ruling. However, the stock’s valuations are considered distressed, trading at 0.22x FY26F Price-to-Book Value, and its substantial net cash position—representing over 62% of its market capitalization—provides a near-term trading upside.
Looking ahead, key policy catalysts are expected to drive future performance. These include the ongoing Section 232 investigation into medical personal protective equipment, with a decision anticipated by May 2026 that could trigger higher national security tariffs. Additionally, “Buy American” mandates are expected to channel institutional demand towards the company’s Texas facility, further supporting its strategic positioning in the US market. While this optimistic outlook is not the prevailing base-case sector view, the risk-reward balance for the stock is deemed favorable at current levels.
